Open-label Extension for Phase 3 Clinical Trials of Simufilam

Stopped early · Phase 3

Conditions studied: Alzheimer Disease

In brief

The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RETHINK-ALZ or REFOCUS-ALZ Phase 3 clinical trials.

Key facts

Study ID
NCT05575076
Run by
Cassava Sciences, Inc.
People needed
1081
Starts
2022-11-07
Expected to finish
2025-01-31
Last updated by the study team
2025-05-23

Who can join

Age: 51 and older, up to 89. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.